Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03593343
Other study ID # NL66264.068.18
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2019
Est. completion date January 13, 2020

Study information

Verified date October 2020
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Excessive fat in the liver is associated with impairments in metabolic health. Low levels of DNL and high levels of hepatic fat oxidation are considered to be protective.

A decrease in glycogen stores has been causally linked to improved whole body fat oxidation. Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low hepatic glycogen stores. Next to hepatic fat oxidation, DNL may be influenced by hepatic glycogen stores. Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It is therefore hypothesized that prolonging fasting time will lower glycogen content and thereby increases fat oxidation and decreases DNL in the liver. To this end, hepatic fat oxidation (plasma marker beta-hydroxybutyrate), de novo lipogenesis, hepatic glycogen content and intrahepatic fat content, will be measured upon a short overnight fast and an extended overnight fast in 13 overweight/obese subjects with hepatic steatosis.


Description:

Rationale:

Excessive fat in the liver is associated with impairments in metabolic health. Hepatic lipid storage can originate from several metabolic pathways, including de novo lipogenesis (DNL). On the other hand, there are several metabolic pathways that can decrease hepatic fat storage, such as hepatic fat oxidation. Therefore, low levels of DNL and high levels of hepatic fat oxidation are considered to be protective.

A decrease in glycogen stores has been causally linked to improved whole body fat oxidation. Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low hepatic glycogen stores. Furthermore, whole body glycogen levels were also linked to DNL and in situations with increased whole body glycogen levels in animal models rates of DNL were also high. Therefore, next to hepatic fat oxidation, DNL may be influenced by hepatic glycogen stores.

Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It is therefore hypothesized that prolonging fasting time will lower glycogen content and thereby increases fat oxidation and decreases DNL in the liver.

Objective:

The primary objective of this study is to investigate to what extent hepatic fat oxidation can be stimulated by lowering hepatic glycogen content during a prolonged overnight fast.

The secondary objective is to investigate whether reductions in hepatic glycogen content are also accompanied by a decrease in DNL. In addition, the metabolic response to a meal (metabolites related to energy metabolism and substrate oxidation) will be studied upon prolonged overnight fasting. Finally, it will be studied whether reducing hepatic glycogen content by prolonged overnight fasting during a few consecutive days lowers intrahepatic fat storage and changes hepatic fat composition.

Study design:

This is a randomized cross-over study.

Study population:

Thirteen healthy overweight/obese males and postmenopausal females, aged between 45-75 years and BMI between 27-38 kg/m2, with liver fat content ≥ 5% will participate in the study. To be able to include enough people with a liver fat content ≥5%, around 27 participants are expected to be screened for liver fat. When liver fat content is <5%, participants will not be included in the study after determination of liver fat content.

Main study parameters/endpoints:

The primary study outcome is hepatic fat oxidation measured as plasma beta-hydroxybutyrate (BHB) levels, which will be measured before and after one night adherence to the fasting protocols. The secondary study outcome is DNL as determined by stable isotope techniques and will also be measured after one night adherence to the fasting protocols. Other study outcomes include hepatic glycogen content, substrate oxidation and plasma metabolites related to energy metabolism (measured before and after one night adherence to the fasting protocols) and intrahepatic fat content and composition (measured after 6 days of adherence to the fasting protocols).


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date January 13, 2020
Est. primary completion date January 8, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria:

- Signed informed consent

- Caucasian (people will be excluded when having a =50% racial African/Asian background)

- Male or postmenopausal female

- Aged 45-75 years at start of the study

- Body mass index (BMI) 27 - 38 kg/m2

- Stable dietary habits (no weight loss or gain >3kg in the past 3 months)

- Sedentary lifestyle (not more than 2 hours of sports per week)

- Liver fat =5% as determined by 1H-MRS

Exclusion Criteria:

- Type 2 diabetes

- Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)

- Contra-indication for MRI (which can be found in appendix II)

- Alcohol consumption of >2 servings per day

- Regular smoking (>5 cigarettes per day)

- No use of medication interfering with investigated study parameters (as determined by responsible physician)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Overnight fasting duration
Subjects will adhere to overnight fasting protocol for 6 days

Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Unilever R&D

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Hepatic glycogen content Measured with 13C-MRS 1 hour
Other Intrahepatic fat accumulation and composition Measured with 1H-MRS 20 minutes
Other Substrate oxidation measured with indirect calorimetry 30 minutes
Other Plasma metabolites related to energy metabolism measured in plasma samples 5 hours
Other Body composition fat mass/fat free mass measured with BodPod 5 minutes
Primary Hepatic fat oxidation measured as plasma BHB levels 5 hours
Secondary De novo lipogenesis (DNL) measured as percentage of palmitate in VLDL-TG originating from DNL 20 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03754920 - Prolonged Fasting With Meditation and Mild Physical Exercise N/A
Completed NCT05272332 - Gastric Ultrasound Prior to Extubation
Completed NCT04247464 - Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients N/A
Completed NCT01067001 - Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Completed NCT01506713 - Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions Phase 1
Completed NCT04514380 - Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
Completed NCT05756868 - The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior N/A
Completed NCT05134207 - The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty N/A
Completed NCT05031598 - Long-term Fasting: Multi-system Adaptations in Humans N/A
Recruiting NCT04501393 - Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Completed NCT05219136 - Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol N/A
Recruiting NCT04625608 - Effect of Premedicant Oral Paracetamol on Gastric Volume and pH Phase 4
Not yet recruiting NCT02562638 - Pre-Procedural Fasting in Cardiac Intervention N/A
Completed NCT01954836 - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial N/A
Completed NCT01949987 - Does Oral Intake Decreases Postoperative Pain Score in Children N/A
Completed NCT01746719 - Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition Phase 1
Completed NCT01713647 - Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions Phase 1
Completed NCT01831700 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions Phase 1